Michael Halpin serves as the Chief Operating Officer (COO) at VERICEL CORP, a leading biotechnology company specializing in advanced therapies for sports medicine and severe burn care. In his role as COO, Halpin oversees the company's operational strategies, ensuring the efficient and effective execution of VERICEL's mission to develop and commercialize innovative treatments. His leadership is instrumental in driving the company's growth and maintaining its position at the forefront of the regenerative medicine industry. Halpin brings a wealth of experience to VERICEL, having held various high-level positions in the life sciences sector. Prior to joining VERICEL, he served in executive roles at several prominent healthcare companies, where he honed his skills in operational management and strategic planning. His background includes significant contributions to the development and launch of new medical technologies, showcasing his ability to navigate complex regulatory environments and bring cutting-edge solutions to market. Under his guidance, VERICEL has successfully expanded its product portfolio and strengthened its market presence. In addition to his operational expertise, Halpin is recognized for his commitment to fostering a culture of innovation and excellence within VERICEL. He has been instrumental in building strong teams and driving continuous improvement across the organization. His strategic vision and dedication to advancing patient care have been key factors in VERICEL's ongoing success. As COO, Halpin continues to play a pivotal role in shaping the future of the company and ensuring its sustained growth in the competitive biotechnology landscape.